Evidence map›Paper›PMID 35904195›Full record

ArticleJournal of the American Heart Association2022

Plasma Levels of Advanced Glycation Endproducts and Risk of Cardiovascular Events: Findings From 2 Prospective Cohorts.

Julio A Lamprea-Montealegre, Alice M Arnold, Robyn L McCLelland, Kenneth J Mukamal, Luc Djousse, Mary L Biggs, David S Siscovick, Russell P Tracy, Paul J Beisswenger, Bruce M Psaty and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Julio A Lamprea-MontealegreCardiology Section San Francisco Veterans Affairs Health Care System San Francisco CA.ORCID 0000-0002-5999-4287
Alice M ArnoldDepartment of Biostatistics, School of Public Health University of Washington Seattle WA.ORCID 0000-0001-9565-0927
Robyn L McCLellandDepartment of Biostatistics, School of Public Health University of Washington Seattle WA.
Kenneth J MukamalDepartment of Medicine Beth Israel Deaconess Medical Center and Harvard Medical School Boston MA.ORCID 0000-0001-8450-6970
Luc DjousseDivision of Aging, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA.ORCID 0000-0002-9902-3047
Mary L BiggsDepartment of Biostatistics, School of Public Health University of Washington Seattle WA.ORCID 0000-0003-0687-9610
David S SiscovickThe New York Academy of Medicine New York NY.ORCID 0000-0003-0461-175X
Russell P TracyDepartment of Pathology and Laboratory Medicine University of Vermont College of Medicine Burlington VT.ORCID 0000-0002-0080-2420
Paul J BeisswengerDepartment of Medicine Dartmouth Geisel School of Medicine Hanover NH.ORCID 0000-0002-6594-6978
Bruce M PsatyCardiovascular Health Research Unit, Department of Medicine, Epidemiology and Health Services University of Washington Seattle WA.ORCID 0000-0002-7278-2190
Joachim H IxDivision of Nephrology, Department of Medicine University of California San Diego CA.
Jorge R KizerCardiology Section San Francisco Veterans Affairs Health Care System San Francisco CA.ORCID 0000-0001-9936-7803
University of Washington · USUniversity of California, San Francisco · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USDartmouth College · USNew York Academy of Medicine · USUniversity of California San Diego · USUniversity of Vermont · US

Funding

CHS Events Follow-up StudyU01HL080295 · UNIVERSITY OF WASHINGTON · 2005 to 2005
$1.1M
NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR001420NHLBI NIH HHS HHSN268200800007CNHLBI NIH HHS HHSN268201200036CNHLBI NIH HHS HHSN268201500003INHLBI NIH HHS HHSN268201800001CNHLBI NIH HHS K24 HL135413NHLBI NIH HHS N01HC55222NHLBI NIH HHS N01HC85079NHLBI NIH HHS N01HC85080NHLBI NIH HHS N01HC85081NHLBI NIH HHS N01HC85082NHLBI NIH HHS N01HC85083NHLBI NIH HHS N01HC85086NHLBI NIH HHS R01 HL094555NHLBI NIH HHS U01 HL080295NHLBI NIH HHS U01 HL130114NIA NIH HHS R01 AG053325
6 · The paper itself

Abstract

Background Advanced glycation endproducts (AGEs) have been linked to cardiovascular disease (CVD) in cohorts with and without diabetes. Data are lacking on prospective associations of various α-dicarbonyl-derived AGEs and incident CVD in the general population. We tested the hypothesis that major plasma AGEs are associated with new-onset CVD in 2 population-based cohorts of differing age and comorbidities. Methods and Results Analyses involved a random subcohort (n=466) from the Cardiovascular Health Study and a case-cohort sample (n=1631) from the Multi-Ethnic Study of Atherosclerosis. Five AGEs and 2 oxidative products were measured by liquid chromatography tandem mass spectrometry. Associations with CVD (myocardial infarction and stroke) were evaluated with Cox regression. Participants in the Cardiovascular Health Study were older than the Multi-Ethnic Study of Atherosclerosis, and had more comorbidities, along with higher levels of all AGEs. During median follow-up of 11 years, 439 participants in the Multi-Ethnic Study of Atherosclerosis and 200 in the Cardiovascular Health Study developed CVD. After multivariable adjustment, carboxymethyl-lysine, 3-deoxyglucosone hydroimidazolones and a summary variable of all measured AGEs (principal component 1) were significantly associated with incident CVD in the Cardiovascular Health Study (HRs [95% CI]: 1.20 [1.01, 1.42], 1.45 [1.23, 1.72], and 1.29 [1.06, 1.56], respectively), but not the Multi-Ethnic Study of Atherosclerosis. Oxidative products were not associated with CVD in either cohort. Conclusions We found α-dicarbonyl-derived AGEs to be associated with CVD in an older cohort, but not in a healthier middle-aged/older cohort. Our results suggest that AGEs may exert detrimental cardiovascular effects only under conditions of marked dicarbonyl and oxidative stress. Further investigation of α-dicarbonyl derivatives could lead to potential new strategies for CVD prevention in high-risk older populations.

Indexed as

AtherosclerosisCardiovascular DiseasesCohort StudiesGlycation End Products, AdvancedHumansMiddle AgedRisk FactorsGlycation End Products, Advancedadvanced glycation endproductsagingcardiovascular disease

Identifiers

PMID35904195
PMCPMC9375486
OpenAlexW4288535429

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.